Trial Profile
Japanese postmarketing surveillance of erlotinib in unresectable recurrent and advanced non-small cell lung cancer that was aggravated following chemotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms POLARSTAR
- Sponsors Chugai Pharmaceutical
- 11 Feb 2012 New trial record
- 01 Oct 2009 Recruitment completed, according to 23rd Annual Congress of the European Respiratory Society.